Abstract

The purpose of this review is to revise and refine the available evidence in support of a clinical guideline for the yearly screening of sero-immunity to hepatitis B as part of ongoing follow-up therapy for patients, ages six to 20 years old, diagnosed with Inflammatory Bowel Disease and on infliximab.

Author Details

Sarybeth Tirado Martinez, DNP, MSN, APRN, FNP-BC; Audrey P. Miller, PhD, MSNEd, ARNP, PPCNP-BC; Deana Goldin, PhD, DNP, APRN, FNP-BC, PMHNP-BC -- Nicole Wertheim College of Nursing and Health Sciences, Florida international University Nicole Wertheim College of Nursing and Health Sciences, Miami, Florida, USA

Sigma Membership

Unknown

Lead Author Affiliation

Florida International University, Miami, Florida, USA

Type

Poster

Format Type

Text-based Document, Video Recording

Study Design/Type

N/A

Research Approach

N/A

Keywords:

Hepatitis B, Inflammatory Bowel Disease, Infliximab

Conference Name

31st International Nursing Research Congress

Conference Host

Sigma Theta Tau International

Conference Location

Virtual Event

Conference Year

2020

Video/Audio Streaming

Rights Holder

All rights reserved by the author(s) and/or publisher(s) listed in this item record unless relinquished in whole or part by a rights notation or a Creative Commons License present in this item record.

All permission requests should be directed accordingly and not to the Sigma Repository.

All submitting authors or publishers have affirmed that when using material in their work where they do not own copyright, they have obtained permission of the copyright holder prior to submission and the rights holder has been acknowledged as necessary.

Acquisition

Proxy-submission

Additional Files

download (71450 kB)

download (81 kB)

Share

COinS
 

Infliximab and the effect on immunity to hepatitis B in patients with inflammatory bowel disease

Virtual Event

The purpose of this review is to revise and refine the available evidence in support of a clinical guideline for the yearly screening of sero-immunity to hepatitis B as part of ongoing follow-up therapy for patients, ages six to 20 years old, diagnosed with Inflammatory Bowel Disease and on infliximab.